iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Changhua site meets international regulatory standards for global medical applications
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
This significant milestone enhances our global regulatory standing
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Subscribe To Our Newsletter & Stay Updated